Retinoid differentiation therapy for common types of acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Retinoid differentiation therapy for common types of acute myeloid leukemia.

Retinoid differentiation therapy for common types of acute myeloid leukemia.

http://www.wikidata.org/entity/Q41723841

about

Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells.RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells.Unlocking the potential of retinoic acid in anticancer therapy.An ATRActive future for differentiation therapy in AML.In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediator Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma?Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines.The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.Effects of lapatinib on cell proliferation and apoptosis in NB4 cells.The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells.

P2860

Q35536200-66F0AC9F-7F12-4A9D-A50F-8E3602E29E23 Q36189756-1640BE6B-9914-4D75-B2F8-1AC38F562B8E Q36504936-77E6A8F8-836D-40E5-BC09-CC6AA98DA0F6 Q37564753-DB9FDCEB-AAAD-4743-8247-7B1EBEAC3EC7 Q38269931-FBB2E3D3-BAC1-44CF-AD42-C69E68943CE2 Q38336112-5F84B345-782D-4CDE-BFA4-263F8144952A Q39023971-B48F8CC6-D1B8-4305-A689-8E62DD304D35 Q39029755-F1B264AE-70A5-4318-BB79-A603FBA6DC53 Q41865268-F31058C4-2111-4289-8682-D2F547FE27AF Q41872280-F4FB7834-18B7-4F34-AD82-0BC0AB101AE7 Q42062405-2F47597A-DC9C-4F69-8D6D-C3D5ECAA5082 Q48517509-4A473FC9-DABD-4CA1-86D5-A0562E5491A0 Q54982375-7DBF7D0B-BB1F-4503-9693-9E5A79384382

P2860

Retinoid differentiation therapy for common types of acute myeloid leukemia.

http://www.wikidata.org/entity/Q41723841

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Retinoid differentiation therapy for common types of acute myeloid leukemia.

@en

type

label

Retinoid differentiation therapy for common types of acute myeloid leukemia.

@en

prefLabel

Retinoid differentiation therapy for common types of acute myeloid leukemia.

@en

P1433

Q41723841-8E30EA76-B23E-43F4-96C5-BEDD89185885

P1476

Q41723841-E697F7B9-58D5-41BA-87A0-6C30B2E80B0E

P2093

Q41723841-0ED0CEFB-A090-46A3-AD26-6C5F327414F4

P2860

Q41723841-0055799E-28C6-4D67-A3C9-135AF9DEAAEF

Q41723841-04A1428D-22A2-4685-A7DA-3105D2B56315

Q41723841-05E99F90-C5EE-4198-A33D-871C7B1A920F

Q41723841-07C46191-A3CA-428A-895F-45A5CB18AAA6

Q41723841-0811DAB7-A7B6-4541-8C1C-B44AFECC403F

Q41723841-098ED9E7-5C47-444E-8489-AFBEA7415048

Q41723841-0C57FC83-0D65-4284-8083-57EF626FBE60

Q41723841-143B6A81-A37C-4AA6-824D-F80C658E8DDF

Q41723841-14D629A8-406B-41BB-A1C5-2BFCFFDE104F

Q41723841-1863E515-12D8-43AE-94D0-6CA8B281BE64

P304

Q41723841-6B346CCD-7179-4592-8982-FFD9CC39E7E4

P31

Q41723841-BF9E7D62-F215-4F5B-8C76-0CCB974DC24A

P356

Q41723841-9ED054A1-B64C-4D4E-B719-BBE9AB12912E

P478

Q41723841-4EFE25AC-AB31-4CF8-BACC-7541354DA913

P50

Q41723841-C993DC86-767D-4B67-A52C-83DE751DA1F3

P577

Q41723841-5EB407D3-3ED7-432E-A65D-90FB7A091FCB

P5875

Q41723841-D7B3722F-764D-4C43-9050-449FF72160F4

P698

Q41723841-AC79A6D5-9868-4126-AFB8-7E4975F27186

P932

Q41723841-13B1D8AA-4BA4-4D68-9CC9-6D7A639EE4D8

P356

P1433

Leukemia Research and Treatment

P1476

Retinoid differentiation therapy for common types of acute myeloid leukemia.

@en

P2093

Philip Hughes

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis

Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML

Glycogen synthase kinase-3: functions in oncogenesis and development

Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology

Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells

Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group

P304

939021

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/939021

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233850312

http://www.w3.org/2001/XMLSchema#string

P698

23213553

http://www.w3.org/2001/XMLSchema#string

P932

3504222

http://www.w3.org/2001/XMLSchema#string